Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment.

Takayuki Hattori, Kuniaki Saito, Masao Takemura, Hiroyasu Ito, Hirotoshi Ohta, Hisayasu Wada, Yoshitatsu Sei, Mitsunobu Kawamura, Mitsuru Seishima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AIM: Statins are effective in lowering cholesterol levels, but cause fatal rhabdomyolysis in susceptible individuals. Because it has been hypothesized that muscle damage could result from alterations in Ca(2+) homeostasis in muscle cells, we tested whether measuring statin-induced changes in intracellular calcium ([Ca(2+)](i)) is useful for predicting susceptibility to statin-muscle damage, using human CD19+ primary B lymphocytes. METHODS: Statin-induced alterations in [Ca(2+)](i) were studied using the human THP-1 cell line and CD19+ primary B lymphocytes. Changes in [Ca(2+)](i) were measured directly in fluo-3- loaded cells using either single or dual-color flow cytometry. RESULTS: The Ca(2+) release study suggested that statin-induced changes in [Ca(2+)](i) were due to Ca(2+) release from ryanodine-sensitive Ca(2+) stores and mitochondrial compartments. Further, statin users who experienced elevated creatine kinase (n=8) exhibited significantly greater statin-induced Ca(2+) release in B cells than healthy volunteers (n=45) and statin users without elevated creatine kinase (n=16), while no difference was seen between the latter two groups. CONCLUSION: Statin-induced Ca(2+) release from ryanodine-sensitive stores and mitochondria may contribute to myotoxicity. The laboratory test for Ca(2+) release using CD19+ primary B lymphocytes may be useful to predict susceptibility to statin-induced muscle toxicity prior to statin use.

Original languageEnglish
Pages (from-to)870-877
Number of pages8
JournalJournal of Atherosclerosis and Thrombosis
Volume16
Issue number6
Publication statusPublished - 01-12-2009
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lymphocytes
Creatine Kinase
B-Lymphocytes
Serum
Muscle
Therapeutics
Ryanodine
Cells
Muscles
Rhabdomyolysis
Mitochondria
Flow cytometry
Muscle Cells
Toxicity
Healthy Volunteers
Flow Cytometry
Homeostasis
Color
Cholesterol

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Biochemistry, medical

Cite this

Hattori, Takayuki ; Saito, Kuniaki ; Takemura, Masao ; Ito, Hiroyasu ; Ohta, Hirotoshi ; Wada, Hisayasu ; Sei, Yoshitatsu ; Kawamura, Mitsunobu ; Seishima, Mitsuru. / Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. In: Journal of Atherosclerosis and Thrombosis. 2009 ; Vol. 16, No. 6. pp. 870-877.
@article{a89cff3e25844fbeb827fc0034637e2c,
title = "Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment.",
abstract = "AIM: Statins are effective in lowering cholesterol levels, but cause fatal rhabdomyolysis in susceptible individuals. Because it has been hypothesized that muscle damage could result from alterations in Ca(2+) homeostasis in muscle cells, we tested whether measuring statin-induced changes in intracellular calcium ([Ca(2+)](i)) is useful for predicting susceptibility to statin-muscle damage, using human CD19+ primary B lymphocytes. METHODS: Statin-induced alterations in [Ca(2+)](i) were studied using the human THP-1 cell line and CD19+ primary B lymphocytes. Changes in [Ca(2+)](i) were measured directly in fluo-3- loaded cells using either single or dual-color flow cytometry. RESULTS: The Ca(2+) release study suggested that statin-induced changes in [Ca(2+)](i) were due to Ca(2+) release from ryanodine-sensitive Ca(2+) stores and mitochondrial compartments. Further, statin users who experienced elevated creatine kinase (n=8) exhibited significantly greater statin-induced Ca(2+) release in B cells than healthy volunteers (n=45) and statin users without elevated creatine kinase (n=16), while no difference was seen between the latter two groups. CONCLUSION: Statin-induced Ca(2+) release from ryanodine-sensitive stores and mitochondria may contribute to myotoxicity. The laboratory test for Ca(2+) release using CD19+ primary B lymphocytes may be useful to predict susceptibility to statin-induced muscle toxicity prior to statin use.",
author = "Takayuki Hattori and Kuniaki Saito and Masao Takemura and Hiroyasu Ito and Hirotoshi Ohta and Hisayasu Wada and Yoshitatsu Sei and Mitsunobu Kawamura and Mitsuru Seishima",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "16",
pages = "870--877",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "6",

}

Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. / Hattori, Takayuki; Saito, Kuniaki; Takemura, Masao; Ito, Hiroyasu; Ohta, Hirotoshi; Wada, Hisayasu; Sei, Yoshitatsu; Kawamura, Mitsunobu; Seishima, Mitsuru.

In: Journal of Atherosclerosis and Thrombosis, Vol. 16, No. 6, 01.12.2009, p. 870-877.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment.

AU - Hattori, Takayuki

AU - Saito, Kuniaki

AU - Takemura, Masao

AU - Ito, Hiroyasu

AU - Ohta, Hirotoshi

AU - Wada, Hisayasu

AU - Sei, Yoshitatsu

AU - Kawamura, Mitsunobu

AU - Seishima, Mitsuru

PY - 2009/12/1

Y1 - 2009/12/1

N2 - AIM: Statins are effective in lowering cholesterol levels, but cause fatal rhabdomyolysis in susceptible individuals. Because it has been hypothesized that muscle damage could result from alterations in Ca(2+) homeostasis in muscle cells, we tested whether measuring statin-induced changes in intracellular calcium ([Ca(2+)](i)) is useful for predicting susceptibility to statin-muscle damage, using human CD19+ primary B lymphocytes. METHODS: Statin-induced alterations in [Ca(2+)](i) were studied using the human THP-1 cell line and CD19+ primary B lymphocytes. Changes in [Ca(2+)](i) were measured directly in fluo-3- loaded cells using either single or dual-color flow cytometry. RESULTS: The Ca(2+) release study suggested that statin-induced changes in [Ca(2+)](i) were due to Ca(2+) release from ryanodine-sensitive Ca(2+) stores and mitochondrial compartments. Further, statin users who experienced elevated creatine kinase (n=8) exhibited significantly greater statin-induced Ca(2+) release in B cells than healthy volunteers (n=45) and statin users without elevated creatine kinase (n=16), while no difference was seen between the latter two groups. CONCLUSION: Statin-induced Ca(2+) release from ryanodine-sensitive stores and mitochondria may contribute to myotoxicity. The laboratory test for Ca(2+) release using CD19+ primary B lymphocytes may be useful to predict susceptibility to statin-induced muscle toxicity prior to statin use.

AB - AIM: Statins are effective in lowering cholesterol levels, but cause fatal rhabdomyolysis in susceptible individuals. Because it has been hypothesized that muscle damage could result from alterations in Ca(2+) homeostasis in muscle cells, we tested whether measuring statin-induced changes in intracellular calcium ([Ca(2+)](i)) is useful for predicting susceptibility to statin-muscle damage, using human CD19+ primary B lymphocytes. METHODS: Statin-induced alterations in [Ca(2+)](i) were studied using the human THP-1 cell line and CD19+ primary B lymphocytes. Changes in [Ca(2+)](i) were measured directly in fluo-3- loaded cells using either single or dual-color flow cytometry. RESULTS: The Ca(2+) release study suggested that statin-induced changes in [Ca(2+)](i) were due to Ca(2+) release from ryanodine-sensitive Ca(2+) stores and mitochondrial compartments. Further, statin users who experienced elevated creatine kinase (n=8) exhibited significantly greater statin-induced Ca(2+) release in B cells than healthy volunteers (n=45) and statin users without elevated creatine kinase (n=16), while no difference was seen between the latter two groups. CONCLUSION: Statin-induced Ca(2+) release from ryanodine-sensitive stores and mitochondria may contribute to myotoxicity. The laboratory test for Ca(2+) release using CD19+ primary B lymphocytes may be useful to predict susceptibility to statin-induced muscle toxicity prior to statin use.

UR - http://www.scopus.com/inward/record.url?scp=77950343590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950343590&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 870

EP - 877

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 6

ER -